COPENHAGEN, DENMARK — February 18, 2026 Bavarian Nordic has secured a USD 22.5 million vaccine supply contract from the Public Health Agency of Canada (PHAC) for its non-replicating mpox and smallpox vaccine, MVA-BN®, reinforcing global public health preparedness against orthopoxvirus threats. The order, executed under an existing 10-year framework agreement established in 2022, includes bulk vaccine manufacturing in 2026 followed by fill-finish and final drug product supply. The procurement underscores continued government prioritization of strategic vaccine stockpiling in response to emerging infectious disease risks.
Science Significance
MVA-BN® (Modified Vaccinia Ankara-Bavarian Nordic) is a next-generation, non-replicating vaccinia-based vaccine engineered to provide immunization against both mpox and smallpox. Unlike traditional replicating smallpox vaccines, the attenuated viral platform is designed to offer improved safety, particularly for immunocompromised populations. The vaccine stimulates protective immune responses without active viral replication, reducing adverse event risks while maintaining immunogenicity. Its dual-indication capability supports both outbreak response and biodefense preparedness, positioning it as a critical biologic countermeasure in orthopoxvirus prevention strategies.
Regulatory Significance
MVA-BN has achieved regulatory approvals across multiple global jurisdictions, reflecting robust clinical safety and immunogenicity data. The vaccine is marketed under different brand names internationally and is authorized for use in populations at risk of mpox or smallpox infection. Regulatory approvals for non-replicating vaccines represent significant progress in biologics innovation, particularly in infectious disease preparedness where safety considerations are paramount. Ongoing procurement contracts further reinforce regulatory confidence in manufacturing consistency, quality control, and pharmacovigilance frameworks governing large-scale immunization programs.
Business Significance
Advertisement
The Canadian order strengthens Bavarian Nordic’s Public Preparedness business segment, bringing secured 2026 orders in this division to approximately DKK 1,400 million. The agreement supports forward manufacturing planning, including bulk antigen production and fill-finish operations. Long-term government framework contracts provide revenue visibility and operational stability, enabling sustained investment in vaccine R&D and production capacity. Public sector procurement remains a cornerstone commercial model for biodefense vaccine developers, ensuring readiness while supporting industry growth in specialized biologics manufacturing.
Patients’ Significance
For populations at risk of orthopoxvirus exposure, vaccine stockpiling translates directly into access readiness during outbreaks. Mpox, which has re-emerged in multiple regions in recent years, can cause severe dermatologic, systemic, and immunologic complications. Availability of a non-replicating vaccine ensures broader immunization eligibility, including vulnerable and immunocompromised individuals who may not tolerate older vaccine platforms. Strategic reserves enable rapid deployment, reducing transmission, morbidity, and healthcare system burden during public health emergencies.
Policy Significance
Government investment in vaccine preparedness reflects evolving national security and public health policy priorities. Canada’s long-term procurement framework aligns with similar initiatives in the United States and Europe aimed at strengthening biodefense infrastructure and outbreak response readiness. Strategic vaccine reserves are now central to pandemic planning, cross-border health security, and emergency response coordination. Public-private partnerships in vaccine manufacturing play a critical role in ensuring supply continuity, regulatory compliance, and rapid deployment capability during global health threats.
The USD 22.5 million contract between Bavarian Nordic and the Government of Canada reinforces the growing importance of orthopoxvirus vaccine preparedness in modern public health strategy. Through sustained manufacturing agreements and international regulatory alignment, MVA-BN continues to anchor global mpox and smallpox prevention frameworks. As infectious disease preparedness remains a top geopolitical and healthcare priority, long-term vaccine procurement partnerships will be instrumental in safeguarding populations and strengthening global biodefense resilience.
Source: Bavarian Nordic press release
